Welcome to this week’s Oddsmaker Top 25 Best and Worst. First, a brief update on the recently weekly performance of the Oddsmaker Top 25 Best and Worst Picks:

1. IMPP — Imperial Petroleum Inc. | OM Score 152.2 (highest OM Score in the book; SMP 24.7, Near Pass, 3/5; EQS 86.1, OLI 57.8, TRS 70.0, ROIC 13.1%, fwd EV/EBITDA 0.2x, fwd EV/Sales 0.09x, net cash/mkt cap +0.90, Holy Trinity 0.97, ~+30% to OM target / ~+73% to SS target). A Greek shipowner operating product tankers and dry-bulk vessels, controlled by the Vafias family. The market treats it as a deep-value micro-cap tanker sitting on a cash pile larger than most of its enterprise value. Bull case: the cheapest name in the book on every multiple (0.2x forward EBITDA), cash equal to ~90% of market cap, and high earnings quality. Bear case: charter/spot-rate cyclicality and related-party governance (Vafias-affiliated management and past dilution). Biggest upside factor: the extreme valuation — near-zero EV multiples with a fortress cash balance. Three main risks to going long: a tanker-rate downcycle, related-party/governance and dilution risk, and micro-cap illiquidity.

2. AII — American Integrity Insurance Group, Inc. | OM Score 146.1 (SMP 21.1, Near Pass, 4/5; near-perfect Holy Trinity 0.996; TRS 93.3 [highest momentum in book], EQS 85.7, ROIC 19.3%, fwd EV/EBITDA 2.0x, net cash/mkt cap +0.51, ~+29% to OM target). A Florida-focused specialty homeowners insurer that came public in 2025. The market views it as a post-reform Florida hard-market winner still early in its life as a public company. Bull case: an almost perfect Holy Trinity (0.996), the strongest price momentum in the book, high earnings quality, a net-cash balance sheet, and 2x EBITDA. Bear case: heavy Florida catastrophe concentration and a short public track record; RAVG is no-data and OLI is low (39.6). Biggest upside factor: the elite Holy Trinity + raw Score combination (0.996 / OM 146). Three main risks to going long: Florida hurricane/catastrophe losses, reserve and reinsurance-cost pressure, and single-state regulatory/litigation exposure.

3. CMCL — Caledonia Mining Corporation Plc | OM Score 135.0 (SMP 3.9, Near Pass, 3/5; EQS 84.9, OLI 63.5, TRS 56.3, ROIC 11.7%, fwd EV/EBITDA 2.9x, fwd FCF/EV −0.20, Holy Trinity 0.96, ~+27% to OM target / ~+82% to SS target). A gold producer whose core asset is the Blanket Mine in Zimbabwe, with the larger Bilboes project in development. The market treats it as a high-leverage gold play carrying Zimbabwe jurisdiction risk. Bull case: strong earnings quality and direct gold-price leverage at under 3x EBITDA, a high Holy Trinity, and large implied upside to the SmartScore target. Bear case: Zimbabwe political/currency/cash-repatriation risk and negative forward free cash flow (−0.20) as Bilboes capex ramps; revisions are the weakest in the book (RAVG 2.1). Biggest upside factor: gold-price leverage combined with a cheap 2.9x EBITDA multiple. Three main risks to going long: Zimbabwe country/currency risk, a gold-price decline, and capex/execution risk on Bilboes (the source of the negative FCF).

4. HRTG — Heritage Insurance Holdings, Inc. | OM Score 133.2 (SMP 1.6, Near Pass, 4/5; TRS 89.9, EQS 86.1, CAS 67.7, ROIC 37.2%, fwd EV/EBITDA 1.6x, net cash/mkt cap +0.51, Holy Trinity 0.91, ~+26% to OM target). A coastal super-regional property & casualty (homeowners) insurer. The market sees a hard-market P&C name trading cheaply against elevated catastrophe exposure. Bull case: the top-ranked earnings quality and near-top momentum in the book, 37% ROIC, a sizable net-cash position, and ~1.6x EBITDA. Bear case: concentrated coastal catastrophe risk and reserve adequacy; RAVG is no-data and OLI is low (42.2). Biggest upside factor: the combination of a very high raw Score and earnings quality (OM 133 / EQS 86) at 1.6x EBITDA. Three main risks to going long: hurricane/catastrophe losses, reinsurance-cost inflation, and reserve/prior-year-development surprises.

5. TREE — LendingTree, Inc. | OM Score 134.7 (SMP 3.5, Near Pass, 4/5; FRM 79.3, CAS 73.3, EQS 62.3, ROIC 25.3%, fwd EV/EBITDA 5.1x, fwd FCF/EV 0.11, net cash/mkt cap −0.75, TRS 3.9 [weakest momentum in book], Holy Trinity 0.92, ~+26% to OM target / ~+83% to SS target). An online marketplace for loans and financial products — mortgage, consumer/personal lending, and insurance lead generation. The market views it as a rate-sensitive lead-gen platform recovering as its insurance vertical booms and rates ease. Bull case: strong forward growth (FRM 79.3), good capital allocation (73.3), 25% ROIC, positive FCF yield, and large SmartScore-target upside. Bear case: the weakest momentum in the book (TRS 3.9), a levered balance sheet (net cash/mkt cap −0.75), and weak revisions (RAVG 9.1). Biggest upside factor: forward-growth acceleration (FRM 79.3) as the insurance segment scales. Three main risks to going long: leverage/refinancing, interest-rate and mortgage-demand sensitivity, and marketing-efficiency/competition pressure in lead generation.

1. HTFL — HeartFlow, Inc. | OM Score −177.2 (SMP −251.4, Near Pass, 4/5; MCR 83.3, BDR 99.1 [most stretched vs. targets in the book], VSR 84.4; ROIC −61.4%, fwd EV/Sales 14.9x, short interest 7.9%, beta 1.89, Holy Trinity 0.29, ~−35% to OM target). An AI cardiac-imaging company whose FFR-CT analysis models coronary blood flow from CT scans; IPO'd in 2025. The market treats it as a high-growth medtech disrupting invasive angiography. Bear case: trades at ~15x sales and 1.5x the model's target with deeply negative returns (−61% ROIC) and the most stretched price-vs-target reading in the book. Bull case (risk to short): reimbursement wins and procedure-volume ramps could sustain the growth narrative. Biggest downside factor: behavioral dislocation (BDR 99.1) — price is furthest above model fair value of any name. Three main risks to going short: a post-IPO momentum bid, reimbursement/adoption catalysts, and its 7.9% short interest amplifying any squeeze.

2. BFLY — Butterfly Network, Inc. | OM Score −120.9 (SMP −199.4, Near Pass, 3/5; MCR 84.0, BDR 91.4, VSR 92.2; ROIC −32.3%, fwd EV/Sales 18.7x, short interest 12.3%, beta 2.19, Holy Trinity 0.44, ~−24% to OM target). A handheld, semiconductor-based point-of-care ultrasound maker. The market views it as a cheap-hardware disruptor of imaging with a software/subscription upside. Bear case: ~19x sales on negative returns, high volatility, and a weak quality profile. Bull case (risk to short): new probe cycles, AI features, or a device-plus-software re-rating. Biggest downside factor: multiple compression (MCR 84) from an unsustainable ~19x sales multiple. Three main risks to going short: 12.3% short interest with beta >2, product-launch or partnership news, and its low absolute price making percentage squeezes violent.

3. AEHR — Aehr Test Systems, Inc. | OM Score −152.2 (SMP −340.4, Strict Pass, 3/5; MCR 88.8, BDR 77.1, VSR 95.7 [near-top squeeze risk]; ROIC −3.9%, fwd EV/Sales 23.6x, short interest 13.2%, beta 4.68, Holy Trinity 0.44, ~−30% to OM target). A maker of semiconductor burn-in and test systems, historically levered to silicon-carbide/EV and now AI-datacenter demand. The market treats it as a boom-bust cyclical whipsawing on customer-concentration news. Bear case: a strict-pass short on Score and SMP at ~24x sales with negligible returns. Bull case (risk to short): a single large order or AI-test design win can double the stock. Biggest downside factor: the extreme Score/SMP breakdown combined with a 24x-sales multiple. Three main risks to going short: an enormous 4.68 beta, 13.2% short interest, and binary customer-order catalysts.

4. ASST — Strive, Inc. | OM Score −170.7 (SMP −310.7, Strict Pass, 5/5 [full short signature]; MCR 85.5, BDR 72.4, VSR 98.9 [highest squeeze risk in book]; ROIC −141.5%, fwd EV/Sales 188x, short interest 25.9%, beta 3.77, Holy Trinity 0.25, ~−34% to OM target). Vivek Ramaswamy's asset-management firm, now operating as a Bitcoin-treasury vehicle (the model still carries a stale "Health Care" sector tag from its Asset Entities predecessor). The market treats it as a leveraged, premium-to-NAV crypto proxy. Bear case: a perfect 5/5 short signature, ~188x sales, and catastrophic returns as the mNAV premium looks unsustainable. Bull case (risk to short): a rising Bitcoin price plus retail enthusiasm can inflate the premium further. Biggest downside factor: the volatility/squeeze profile (VSR 98.9) paired with a treasury-premium that can collapse fast. Three main risks to going short: 25.9% short interest with beta 3.77, Bitcoin-price rallies, and treasury-vehicle capital-raise/announcement pops.

5. SNOW — Snowflake Inc. | OM Score −100.5 (SMP −270.5, Near Pass, 3/5; MCR 88.3, BDR 97.5, VSR 73.4; ROIC −24.4%, fwd EV/Sales 17.6x, short interest 5.5%, beta 1.47, Holy Trinity 0.74, ~−20% to OM target). The leading cloud data-warehouse/"data cloud" platform. The market views it as a premier AI-data beneficiary with durable consumption growth. Bear case: ~18x sales and price far above model targets (BDR 97.5) with still-negative GAAP returns. Bull case (risk to short): AI-workload acceleration and margin inflection are the consensus long thesis and could keep the multiple elevated. Biggest downside factor: behavioral dislocation (BDR 97.5) — richly valued versus the model's fair value. Three main risks to going short: it's the highest-quality, most-owned name on this list (lowest squeeze mechanics but strongest fundamental bid), AI-narrative multiple support, and beat-and-raise quarters.

6. UMAC — Unusual Machines, Inc. | OM Score −168.0 (SMP −237.7, Near Pass, 4/5; MCR 83.0, BDR 73.6, VSR 98.4; ROIC −2.9%, fwd EV/Sales 13.7x, short interest 18.9%, beta 4.57, Holy Trinity 0.39, ~−33% to OM target). A small US maker of FPV drones and drone components, boosted by "Made-in-America" defense-drone sentiment (and prior Trump-family investor attention). The market treats it as a policy/theme momentum stock. Bear case: ~14x sales, negligible returns, and a valuation driven by narrative rather than earnings. Bull case (risk to short): US drone-sourcing policy or defense contracts could re-ignite the theme. Biggest downside factor: the squeeze/volatility profile (VSR 98.4) atop thin fundamentals. Three main risks to going short: beta 4.57 with 18.9% short interest, defense/policy headline catalysts, and micro-float mechanics.

7. RBRK — Rubrik, Inc. | OM Score −51.2 (SMP −210.0, Near Pass, 3/5; MCR 87.2, BDR 94.2, VSR 79.2; ROIC −122.0%, fwd EV/Sales 11.6x, short interest 6.2%, beta 1.96, Holy Trinity 0.70, ~−10% to OM target). A cloud data-security and backup/recovery ("cyber resilience") platform. The market views it as a high-growth security name riding ransomware-recovery demand. Bear case: ~12x sales, price above target, and deeply negative returns (−122% ROIC). Bull case (risk to short): security spending is defensive and Rubrik's growth/retention could justify the multiple. Biggest downside factor: multiple compression (MCR 87) if security-software multiples normalize. Three main risks to going short: strong secular security demand, a relatively modest ~−10% implied downside (least stretched of the top tier), and beat-driven re-rating.

8. GTLB — GitLab Inc. | OM Score −31.4 (SMP −175.6, Composite, 3/5; MCR 78.4, BDR 96.0, VSR 88.1; ROIC −2.7%, fwd EV/Sales 5.0x, short interest 11.3%, beta 1.70, Holy Trinity 0.76, ~−6% to OM target). An all-in-one DevOps/DevSecOps software platform. The market treats it as an AI-coding beneficiary with improving margins. Bear case: price well above the model's target (BDR 96) even after de-rating to ~5x sales. Bull case (risk to short): AI-assisted-development tailwinds and a possible takeout keep a floor under it. Biggest downside factor: behavioral dislocation (BDR 96). Three main risks to going short: M&A/takeout speculation, the AI-coding narrative, and only ~−6% implied downside (thin margin of safety on the short).

9. HIMS — Hims & Hers Health, Inc. | OM Score −73.9 (SMP −212.7, Near Pass, 2/5 [weakest short signature in book]; MCR 64.9, BDR 94.6, VSR 96.1; ROIC −8.2%, fwd EV/Sales 2.3x, short interest 26.7%, beta 2.37, Holy Trinity 0.77, ~−15% to OM target). A direct-to-consumer telehealth platform (dermatology, sexual health, weight-loss/GLP-1). The market views it as a fast-growing consumer-health brand. Bear case: price stretched far above target with a volatile, momentum-driven tape. Bull case (risk to short): GLP-1 and subscriber growth are real and it's actually profitable-ish on an adjusted basis — the thinnest short signature here (2/5). Biggest downside factor: behavioral/volatility dislocation (BDR 94.6, VSR 96.1). Three main risks to going short: a very high 26.7% short interest (severe squeeze potential), GLP-1/weight-loss momentum, and its comparatively reasonable ~2.3x sales multiple.

10. U — Unity Software Inc. | OM Score −32.0 (SMP −184.1, Composite, 3/5; MCR 82.5, BDR 92.2, VSR 86.6; ROIC −10.3%, fwd EV/Sales 8.6x, short interest 7.8%, beta 2.46, Holy Trinity 0.73, ~−6% to OM target). The dominant real-time 3D game engine plus an advertising/monetization business. The market treats it as a turnaround after its ad-platform (Grow/Vector) reset. Bear case: ~9x sales and price above target despite ongoing losses. Bull case (risk to short): the ad-engine rebuild and AI/3D tooling could drive a re-rating. Biggest downside factor: behavioral dislocation (BDR 92). Three main risks to going short: turnaround-execution upside, beta 2.46 volatility, and only ~−6% implied downside.

11. AI — C3.ai, Inc. | OM Score −157.7 (SMP −221.8, Near Pass, 4/5; MCR 70.5, BDR 84.3, VSR 95.9; ROIC −58.4%, fwd EV/Sales 4.8x, fwd FCF/EV −0.10, short interest 29.8% [highest in book], beta 2.28, Holy Trinity 0.01 [near-worst], ~−31% to OM target). An enterprise-AI application-software vendor. The market treats it as a pure-play AI name with heavy government/energy exposure and persistent losses. Bear case: near-worst Holy Trinity (0.01), negative FCF, and a weak Score/SMP breakdown. Bull case (risk to short): any "AI" headline or large contract can spike it, and 29.8% short interest is combustible. Biggest downside factor: the collapse in fundamental quality (Holy Trinity 0.01) alongside cash burn. Three main risks to going short: the highest short interest in the book (extreme squeeze risk), AI-narrative headline sensitivity, and government-contract announcements.

12. COIN — Coinbase Global, Inc. | OM Score −58.8 (SMP −219.0, Near Pass, 4/5; MCR 92.5 [highest compression risk in book], BDR 76.8, VSR 84.1; ROIC −5.4%, fwd EV/Sales 8.4x, short interest 8.3%, beta 2.51, Holy Trinity 0.34, ~−12% to OM target). The largest US crypto exchange. The market views it as the blue-chip, regulated crypto-cycle proxy. Bear case: the book's highest multiple-compression risk (MCR 92.5) — earnings are hostage to crypto volumes that can evaporate. Bull case (risk to short): a crypto bull market and stablecoin/regulatory tailwinds can drive huge upside. Biggest downside factor: multiple compression (MCR 92.5) on cyclical, volume-dependent earnings. Three main risks to going short: Bitcoin/crypto rallies, beta 2.51, and regulatory-clarity or product (stablecoin) catalysts.

13. LPTH — LightPath Technologies, Inc. | OM Score −92.8 (SMP −150.5, Near Pass, 3/5; MCR 80.1, BDR 81.1, VSR 95.2; ROIC −24.9%, fwd EV/Sales 9.8x, short interest 15.9%, beta 2.93, Holy Trinity 0.59, ~−18% to OM target). A maker of infrared optics and optical components with growing defense/imaging exposure. The market treats it as a small-cap defense-optics momentum play. Bear case: ~10x sales on negative returns, richly valued versus target. Bull case (risk to short): defense contracts and a pivot to higher-value engineered optics could sustain the run. Biggest downside factor: the volatility/squeeze profile (VSR 95.2) on a thin-float name. Three main risks to going short: 15.9% short interest with beta 2.93, defense-order catalysts, and micro-cap liquidity.

14. SBET — SharpLink, Inc. | OM Score −90.8 (SMP −291.8, Near Pass, 5/5 [full short signature]; MCR 88.7, BDR 64.7, VSR 95.1; ROIC −183.6%, fwd EV/Sales 27.9x, short interest 18.6%, beta 2.46, Holy Trinity 0.25, ~−18% to OM target). Formerly a sports-betting affiliate-marketing firm, now an Ethereum-treasury company holding ETH on its balance sheet. The market treats it as a leveraged ETH proxy trading at a premium to crypto holdings. Bear case: a perfect 5/5 short signature, ~28x sales, and −184% ROIC as the treasury premium looks fragile. Bull case (risk to short): a rising Ether price plus treasury-accumulation announcements can inflate the premium. Biggest downside factor: the extreme Score/SMP breakdown plus a collapsing mNAV premium (MCR 88.7). Three main risks to going short: Ethereum rallies, 18.6% short interest with beta 2.46, and capital-raise/ETH-purchase headlines.

15. WGS — GeneDx Holdings Corp. | OM Score −59.1 (SMP −214.9, Near Pass, 5/5; MCR 78.9, BDR 91.4, VSR 81.2; ROIC −26.5%, fwd EV/Sales 4.9x, short interest 19.6%, beta 0.78 [lowest in book], Holy Trinity 0.22, ~−12% to OM target). A genomic/exome-sequencing diagnostics company focused on rare disease. The market views it as a genomics turnaround that has scaled exome volumes sharply. Bear case: a 5/5 short signature and weak quality (Holy Trinity 0.22) after a huge run. Bull case (risk to short): exome-testing volume growth and reimbursement momentum are genuine — and the low 0.78 beta means it doesn't behave like the meme names. Biggest downside factor: the full short signature combined with a stretched price-vs-target (BDR 91.4). Three main risks to going short: continued exome-volume beats, 19.6% short interest, and the low beta making it a "grind-up" rather than fade.

16. PLSE — Pulse Biosciences, Inc. | OM Score −169.4 (SMP −309.4, Strict Pass, 5/5; MCR 85.5, BDR 99.2 [most stretched in book], VSR 59.1; ROIC −73.1%, fwd EV/Sales 861x [essentially pre-revenue], short interest 4.2%, beta 0.74, Holy Trinity 0.28, ~−33% to OM target). A medical-device company commercializing nanosecond-pulsed-field ("Nano-Pulse") tissue-ablation technology. The market treats it as a pre-revenue clinical-stage story valued on future indications (cardiac, thyroid). Bear case: a strict-pass 5/5 short at ~861x sales with the most stretched price-to-target reading in the entire book. Bull case (risk to short): FDA clearances or clinical data in new indications could re-rate it higher. Biggest downside factor: behavioral dislocation (BDR 99.2) at a pre-revenue multiple. Three main risks to going short: FDA/clinical catalysts, a low 4.2% short interest and 0.74 beta (so it can drift up without squeeze pressure), and its concentrated insider/backer ownership.

17. SPCE — Virgin Galactic Holdings, Inc. | OM Score −133.1 (SMP −205.4, Near Pass, 5/5; MCR 77.7, BDR 66.8, VSR 98.6; ROIC −35.2%, fwd EV/Sales 8.1x, fwd FCF/EV −0.51 [heaviest cash burn in book], short interest 25.5%, beta 3.72, Holy Trinity 0.001 [worst in book], ~−26% to OM target). A suborbital space-tourism operator building its next-gen Delta-class ships. The market treats it as a speculative, pre-scale-revenue story burning cash toward a 2026 commercial ramp. Bear case: the worst Holy Trinity in the book (0.001) and enormous cash burn (FCF/EV −0.51) with a 5/5 short signature. Bull case (risk to short): Delta-ship milestones or capital raises can spike a heavily-shorted low-priced stock. Biggest downside factor: cash burn and dilution risk against near-zero fundamental quality. Three main risks to going short: 25.5% short interest with beta 3.72 (violent squeeze potential), spaceflight/milestone headlines, and its sub-$5 price magnifying percentage moves.

18. SDGR — Schrödinger, Inc. | OM Score −73.5 (SMP −136.6, Near Pass, 4/5; MCR 71.1, BDR 90.2, VSR 93.2; ROIC −12.2%, fwd EV/Sales 4.9x, fwd FCF/EV −0.13, short interest 14.7%, beta 2.22, Holy Trinity 0.03, ~−14% to OM target). A computational drug-discovery software company that also co-develops its own drug pipeline. The market views it as a physics-based-simulation platform with optionality on its wholly-owned pipeline. Bear case: near-bottom Holy Trinity (0.03), negative FCF, and price stretched above target. Bull case (risk to short): software-revenue acceleration or a pipeline/partnership readout could re-rate it. Biggest downside factor: weak fundamental quality (Holy Trinity 0.03) plus cash burn. Three main risks to going short: clinical/partnership catalysts, 14.7% short interest with beta 2.22, and lumpy software-license revenue that can beat.

19. FCEL — FuelCell Energy, Inc. | OM Score −95.0 (SMP −162.8, Near Pass, 5/5; MCR 76.7, BDR 74.2, VSR 96.3; ROIC −25.6%, fwd EV/Sales 7.4x, fwd FCF/EV −0.07, short interest 19.9%, beta 2.72, Holy Trinity 0.03, ~−19% to OM target). A stationary fuel-cell power-platform maker (carbonate fuel cells, distributed generation). The market treats it as a perennially-dilutive clean-energy story riding hydrogen/AI-datacenter-power sentiment. Bear case: a 5/5 short signature, chronic cash burn, and near-bottom quality. Bull case (risk to short): hydrogen policy or datacenter-power demand narratives can spark sharp rallies. Biggest downside factor: the volatility/squeeze profile (VSR 96.3) atop weak fundamentals and dilution. Three main risks to going short: 19.9% short interest with beta 2.72, clean-energy/datacenter-power headlines, and equity-raise-timing volatility.

20. NVTS — Navitas Semiconductor Corporation | OM Score −231.8 (most negative OM Score in the book; SMP −371.8, Strict Pass, 4/5; MCR 85.0, BDR 58.8, VSR 95.0; ROIC −52.1%, fwd EV/Sales 46.1x, short interest 15.1%, beta 4.74 [highest in book], Holy Trinity 0.15, ~−46% to OM target [largest implied downside]). A gallium-nitride and silicon-carbide power-semiconductor designer that re-rated violently on an NVIDIA 800V-datacenter-power partnership. The market treats it as a high-beta AI-power-infrastructure bet. Bear case: the worst Score/SMP in the book, ~46x sales, and the largest implied downside (~−46%). Bull case (risk to short): NVIDIA/AI-power design-win momentum can extend the mania. Biggest downside factor: the extreme Score/SMP breakdown paired with a 46x-sales multiple. Three main risks to going short: the highest beta in the book (4.74), AI/NVIDIA partnership headlines, and 15.1% short interest.

21. FIG — Figma, Inc. | OM Score −53.2 (SMP −203.1, Near Pass, 3/5; MCR 83.6, BDR 80.4, VSR 81.6; ROIC −103.9%, fwd EV/Sales 7.9x, short interest 11.3%, beta 1.17, Holy Trinity 0.77, ~−10% to OM target). The collaborative interface-design software platform, public since its 2025 IPO. The market views it as a category-defining design tool expanding into AI-assisted product development. Bear case: negative returns (−104% ROIC, IPO-comp distorted) and price above target after the post-IPO run. Bull case (risk to short): a beloved product, strong net retention, and AI-design features underpin a durable premium. Biggest downside factor: multiple compression (MCR 84) as post-IPO enthusiasm fades. Three main risks to going short: post-IPO lockup/momentum dynamics, the AI-design narrative, and only ~−10% implied downside with a modest 1.17 beta.

22. AMPL — Amplitude, Inc. | OM Score −33.3 (SMP −176.8, Composite, 2/5 [weak short signature]; MCR 73.4, BDR 93.9, VSR 79.1; ROIC −46.3%, fwd EV/Sales 3.4x, short interest 6.1%, beta 1.83, Holy Trinity 0.65, ~−7% to OM target). A digital-analytics/product-intelligence software platform. The market treats it as a recovering SaaS name stabilizing net-revenue retention. Bear case: price above target (BDR 93.9) with negative returns. Bull case (risk to short): at only ~3.4x sales with a 2/5 short signature and improving retention, it's the least-conviction short here — a re-acceleration would hurt. Biggest downside factor: behavioral dislocation (BDR 93.9). Three main risks to going short: the thin 2/5 signature and low ~−7% downside, potential enterprise-deal re-acceleration, and its relatively cheap multiple.

23. RUM — Rumble, Inc. | OM Score −105.0 (SMP −266.0, Near Pass, 5/5; MCR 84.6, BDR 68.2, VSR 83.9; ROIC −14.1%, fwd EV/Sales 8.8x, short interest 6.7%, beta 3.25, Holy Trinity 0.34, ~−21% to OM target; note P/SS target 0.41). A video-sharing and cloud-services platform positioned as a free-speech alternative to YouTube, with a crypto/Bitcoin-treasury and Tether-backed capital angle. The market treats it as a politically-themed growth-and-crypto story. Bear case: a 5/5 short signature, ~9x sales, and negative returns. Bull case (risk to short): its Bitcoin treasury, Tether backing, and a loyal user base can drive sentiment-fueled spikes — and note the model's SmartScore target actually sits above price (P/SS 0.41), an internal signal split. Biggest downside factor: the full short signature against a rich sales multiple. Three main risks to going short: beta 3.25 with crypto/treasury catalysts, political/user-growth sentiment, and the conflicting SS-target signal.

24. MP — MP Materials Corp. | OM Score −59.9 (SMP −236.0, Near Pass, 4/5; MCR 87.5, BDR 60.0, VSR 92.5; ROIC −2.3%, fwd EV/Sales 16.9x, short interest 15.9%, beta 2.16, Holy Trinity 0.38, ~−12% to OM target). The largest US rare-earth miner (Mountain Pass) building magnet-manufacturing capacity, with a DoD price-floor and equity partnership. The market treats it as the strategic domestic rare-earth/magnet champion. Bear case: ~17x sales and high compression risk (MCR 87.5) with negligible current returns. Bull case (risk to short): US-government backing, rare-earth supply-security policy, and magnet-capacity ramp make this a politically-supported name — the most dangerous short on the list fundamentally. Biggest downside factor: multiple compression (MCR 87.5) if rare-earth prices don't cooperate. Three main risks to going short: government/DoD support and pricing floors, rare-earth price spikes, and 15.9% short interest with beta 2.16.

25. BBNX — Beta Bionics, Inc. | OM Score −87.0 (SMP −139.9, Near Pass, 3/5; MCR 68.8, BDR 92.4, VSR 85.2; ROIC −25.6%, fwd EV/Sales 4.4x, fwd FCF/EV −0.13, short interest 16.9%, beta 1.09, Holy Trinity 0.31, ~−17% to OM target). A medical-device maker of the iLet "bionic pancreas" automated insulin-delivery system. The market views it as an insulin-pump challenger taking share in automated diabetes management. Bear case: negative returns, cash burn, and price stretched well above target (BDR 92.4). Bull case (risk to short): pump-placement growth and payer coverage are real clinical tailwinds, and the low 1.09 beta means it won't necessarily crack quickly. Biggest downside factor: behavioral dislocation (BDR 92.4) plus negative FCF. Three main risks to going short: device-adoption/coverage catalysts, 16.9% short interest, and competitive-dynamics surprises in the insulin-pump market.

Thank you for reading this week’s issue of The Oddsmaker. If you would like to view more content like this, or access the Oddsmaker Universe and find every stock tracked by the Oddsmaker all in one place, visit our website:

See you next week.

- The Oddsmaker Team

Disclosure & Disclaimer

The Oddsmaker is a financial media and research publication provided for informational and educational purposes only. Nothing contained herein constitutes investment advice, a recommendation to buy or sell any security, or legal, tax, or accounting advice. The Oddsmaker, its affiliates, employees, contributors, related parties, and associated accounts may hold long, short, or other positions in securities discussed and may buy or sell such securities without notice. Any scores, rankings, ratings, probabilities, expected returns, forecasts, analytics, models, simulations, or backtested results are hypothetical analytical opinions based on assumptions and methodologies that may prove incorrect. They are not guarantees of future performance or outcomes. Information is obtained from sources believed to be reliable; however, The Oddsmaker makes no representation or warranty as to its accuracy, completeness, or timeliness. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Readers are solely responsible for conducting their own due diligence and consulting qualified financial, legal, tax, and accounting professionals before making investment decisions.

© The Oddsmaker. All rights reserved.